Generate Biomedicines, Inc. GENB Reclassification Of Warrant Liability To Equity Upon Initial Public Offering
Other financials
Where this comes from
Reported directly by Generate Biomedicines, Inc. in its filing.
Tagged under the XBRL concept ck0002100782:ReclassificationOfWarrantLiabilityToEquityUponInitialPublicOffering.
The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Generate Biomedicines, Inc. 's reclassification of warrant liability to equity upon initial public offering.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Generate Biomedicines, Inc. 's reclassification of warrant liability to equity upon initial public offering?
- Generate Biomedicines, Inc. (GENB) reported reclassification of warrant liability to equity upon initial public offering of $1.57M in Q1 2026.